Compare Abeona Therapeutics Inc (ABEO) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs EPAM Systems Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while EPAM Systems Inc trades at $86.01 (market cap $4.68B). The key difference: EPAM Systems Inc is far larger — about 12.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | EPAM | |
|---|---|---|
Market Cap | $373.32M | $4.68B |
Sector | Health | Technology |
52-Week High | $7.23 | $221.40 |
52-Week Low | $4.17 | $76.04 |
Enterprise Value | $228.22M | $3.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EPAM Systems trades at $89.55, up 1.45% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 12.48 and P/S of 0.87, while revenue grew to $5.46B in 2025. Recent news highlights EPAM's AI partnership successes and upcoming Q2 2026 earnings, with analyst consensus strongly favoring Buy ratings (64.87%) and a $130.90 price target suggesting significant upside.
The outlook remains positive given EPAM's solid fundamentals and AI-driven growth, but risks include competitive pressures in IT services and market volatility. Institutional sentiment is bullish, though technical indicators warn of near-term resistance. Investors should weigh the strong analyst support against recent price weakness and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
